Premier Alternatives

Ashvattha Therapeutics

Redwood City, CA · Founded 2015 · Privately Held (backing)

Developer of hydroxyl dendrimer therapeutics designed to meet the unmet medical needs in oncology, ophthalmology and inflammatory diseases. Ashvattha Therapeutics is based in Redwood City, CA and was founded in 2015. It was valued at $310 million at its later-stage round in Jan 2025, the last priced event on record. It has raised $217 million across 4 recorded rounds; the latest was a $60.2 million later-stage round in Apr 2021.

PMV mark · valuation
$310.0M
Oct 2026
Priced at
its later-stage round
Jan 2025
Total raised
$217.2M
Last round
Later Stage VC
Apr 2021

Ashvattha Therapeutics key facts

as of Oct 2026
  • Developer of hydroxyl dendrimer therapeutics designed to meet the unmet medical needs in oncology, ophthalmology and inflammatory diseases.
  • Ashvattha Therapeutics is valued at approximately $310.0M as of Oct 2026, set at its later-stage round, Jan 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $217.2M across 4 recorded rounds; the latest was Later Stage VC ($60.2M) in Apr 2021.
  • Notable investors include Evolution VC Partners, Tribe Capital, TEDCO, Sand Hill Angels, Social Capital — 37 tracked in total.
  • Ashvattha Therapeutics has filed 7 Form Ds with the SEC since 2016, most recently Dec 2022 ($60.2M sold to 107 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$310.0M

Valued at $310.0M at its later-stage round, Jan 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Ashvattha Therapeutics with a free account
  • ·The complete investor list: 37 names
  • ·Watch Ashvattha Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Ashvattha Therapeutics funding rounds

4 rounds
Apr 2021Later Stage VC$60.2MSEC filing▮
May 2019Seed Round$250KSEC filing▮
May 2018Seed Round$400KSEC filing▮
Feb 2016Seed Round$300KSEC filing▮
Full funding history →

Ashvattha Therapeutics valuation

Ashvattha Therapeutics was valued at $310 million at its later-stage round in Jan 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Ashvattha Therapeutics raised?

Ashvattha Therapeutics has raised $217 million in total; 4 of its rounds are on record, from 2016 on. The largest on record was a $60.2 million later-stage round in Apr 2021.

Ashvattha Therapeutics has filed 7 Form Ds with the SEC since 2016, most recently in Dec 2022 ($60.2 million sold to 107 investors).

Ashvattha Therapeutics investors

37 investors are on record for Ashvattha Therapeutics, including Evolution VC Partners, Tribe Capital, TEDCO and Sand Hill Angels. By type, the record holds 9 venture capital firms, 1 family office and 1 hedge fund. The later-stage round in Apr 2021 drew 107 investors.

About Ashvattha Therapeutics

Developer of hydroxyl dendrimer therapeutics designed to meet the unmet medical needs in oncology, ophthalmology and inflammatory diseases. The company's therapeutics selectively target actively endocytosing cells such as reactive microglia and macrophages responsible for chronic inflammation and disease progression within the body, enabling medical practitioners to treat patients with improved efficacy and reduced side effects.

Sector
Healthcare
HQ
Redwood City, CA, United States
Founded
2015
Employees
31
Website
avttx.com/
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.